Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Berger

Showing results (121-130 of 770) with videos related to

Pageof 77
Sort By:
Monatshefte Fur Chemie|July 31, 2023
Vapor phase-grown TiO<sub>2</sub> and ZnO nanoparticles inside electrospun polymer fibers and their calcination-induced organizationHasan Razouq, Thomas Berger, Nicola Hüsing, et al.
Frontiers in Psychology|April 17, 2023
The psychological impact of genocide on the YazidisJan Ilhan Kizilhan, Thomas Berger, Laura Sennhauser, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|June 10, 2021
Kurt Jellinger 90: his contribution to neuroimmunologyAssunta Dal-Bianco, Romana Höftberger, Hans Lassmann, et al.
European Journal of Neurology|October 22, 2020
Immunology of COVID-19 and disease-modifying therapies: The good, the bad and the unknownTobias Zrzavy, Isabella Wimmer, Paulus S Rommer, et al.
Journal of Medical Economics|December 8, 2018
Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in AustriaEvelyn Walter, Thomas Berger, Barbara Bajer-Kornek, et al.
European Journal of Dermatology : EJD|December 25, 2008
Tinea barbae spreading to locus minoris resistentiaeChristina S Sander, Olaf Sander, Ayman Khatib, et al.
Nature Reviews. Neurology|June 26, 2013
The spectrum of MOG autoantibody-associated demyelinating diseasesMarkus Reindl, Franziska Di Pauli, Kevin Rostásy, et al.
Expert Review of Clinical Pharmacology|November 14, 2012
Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosisOscar Fernandez, Thomas Berger, Hans-Peter Hartung, et al.
Journal of Medical Internet Research|June 12, 2025
Digital Mental Health Interventions for the Prevention and Treatment of Social Anxiety Disorder in Children, Adolescents, and Young Adults: Systematic Review and Meta-Analysis of Randomized Controlled TrialsNoemi Walder, Alessja Frey, Thomas Berger, et al.
Pharmacological Reviews|May 8, 2024
Novel and Emerging Treatments to Target Pathophysiological Mechanisms in Various Phenotypes of Multiple SclerosisGabriel Bsteh, Assunta Dal Bianco, Tobias Zrzavy, et al.
Pageof 77

Showing results (121-130 of 770) with videos related to

Sort By:
Pageof 77
Monatshefte Fur Chemie|July 31, 2023
Vapor phase-grown TiO<sub>2</sub> and ZnO nanoparticles inside electrospun polymer fibers and their calcination-induced organizationHasan Razouq, Thomas Berger, Nicola Hüsing, et al.
Frontiers in Psychology|April 17, 2023
The psychological impact of genocide on the YazidisJan Ilhan Kizilhan, Thomas Berger, Laura Sennhauser, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|June 10, 2021
Kurt Jellinger 90: his contribution to neuroimmunologyAssunta Dal-Bianco, Romana Höftberger, Hans Lassmann, et al.
European Journal of Neurology|October 22, 2020
Immunology of COVID-19 and disease-modifying therapies: The good, the bad and the unknownTobias Zrzavy, Isabella Wimmer, Paulus S Rommer, et al.
Journal of Medical Economics|December 8, 2018
Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in AustriaEvelyn Walter, Thomas Berger, Barbara Bajer-Kornek, et al.
European Journal of Dermatology : EJD|December 25, 2008
Tinea barbae spreading to locus minoris resistentiaeChristina S Sander, Olaf Sander, Ayman Khatib, et al.
Nature Reviews. Neurology|June 26, 2013
The spectrum of MOG autoantibody-associated demyelinating diseasesMarkus Reindl, Franziska Di Pauli, Kevin Rostásy, et al.
Expert Review of Clinical Pharmacology|November 14, 2012
Historical overview of the rationale for the pharmacological use of prolonged-release fampridine in multiple sclerosisOscar Fernandez, Thomas Berger, Hans-Peter Hartung, et al.
Journal of Medical Internet Research|June 12, 2025
Digital Mental Health Interventions for the Prevention and Treatment of Social Anxiety Disorder in Children, Adolescents, and Young Adults: Systematic Review and Meta-Analysis of Randomized Controlled TrialsNoemi Walder, Alessja Frey, Thomas Berger, et al.
Pharmacological Reviews|May 8, 2024
Novel and Emerging Treatments to Target Pathophysiological Mechanisms in Various Phenotypes of Multiple SclerosisGabriel Bsteh, Assunta Dal Bianco, Tobias Zrzavy, et al.
Pageof 77